scholarly journals Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium

Development ◽  
2012 ◽  
Vol 140 (1) ◽  
pp. 66-75 ◽  
Author(s):  
A. Hirata ◽  
J. Utikal ◽  
S. Yamashita ◽  
H. Aoki ◽  
A. Watanabe ◽  
...  
2013 ◽  
Vol 126 (1) ◽  
pp. e1.1-e1 ◽  
Author(s):  
Akihiro Hirata ◽  
Jochen Utikal ◽  
Satoshi Yamashita ◽  
Hitomi Aoki ◽  
Akira Watanabe ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4246-4246
Author(s):  
Yusuf Baran ◽  
Emel Basak Gencer ◽  
Aylin Camgoz ◽  
Ferit Avcu ◽  
Ali Ugur Ural

Abstract Abstract 4246 Chronic myeloid leukemia (CML) is a hematological malignancy resulting from the reciprocal translocation of chromosomes 9 and 22 that generates BCR/ABL oncogene. Nilotinib is a rationally designed, specific BCR/ABL tyrosine kinase inhibitor. Ceramide is a novel regulator of cell growth and proliferation, differentiation, senescence, cell cycle and also acts a strong apoptotic molecule while its conversion to antiapoptotic glucosyle ceramide (GC) and sphingosine-1-phosphate (S1P) by glucosyle ceramide synthase (GCS) and sphingosine kinase-1 (SK-1) enzymes result in more aggressive and resistant cancers. In this study, we studied the roles of ceramide metabolising genes in nilotinib induced apoptosis and possibility of increasing the sensitivity of BCR/ABL positive K562 and Meg-01 cells to nilotinib through targeting ceramide metabolism. The cytotoxicity analyses of nilotinib, C8:ceramide to induce de novo generation of ceramides, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) to inhibit GCS and SK1 inhibitor were conducted by XTT cell proliferation assay. The changes in caspase-3 enzyme activity and mitochondrial membrane potential (MMP) were measured by caspase-3 colorimetric assay and JC-1 MMP detection kit, respectively. Expression analyses of ceramide synthase (LASS) genes, SK-1 and GCS genes were performed by RT-PCR. We have shown that nilotinib induces apoptosis and inhibits cell-cycle progression in K562 and Meg-01 cells in a dose dependent manner. We have shown significant synergistic apoptotic effects of nilotinib in combination with C8:ceramide or PDMP or SK-1 inhibitor by XTT cell proliferation assay in addition to the changes in caspase-3 enzyme activity and changes in mitochondrial membrane potential, as compared to any agent alone. These results revealed that increasing de novo generation of ceramides or inhibiting conversion of ceramides to antiapoptotic GC or S1P increased sensitivity of BCR/ABL CML cells to nilotinib. More importantly, RT-PCR results revealed that there were significant decreases in expression levels of SK1 in response to increasing concentrations of nilotinib. On the other hand increases in expression levels of LASS2, -4, -5, and -6 ceramide synthase genes were determined in a dose dependent manner as compared to untreated controls. It was shown for the first time by this study that targeting ceramide metabolism in addition to inhibition of BCR/ABL by nilotinib induces apoptosis synergistically in BCR/ABL positive K562 and Meg-01 CML cells. This study was supported by The Scientific and Technological Council of Turkey Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2433-2433
Author(s):  
Hirokazu Tanaka ◽  
Itaru Matsumura ◽  
Yusuke Satoh ◽  
Sachiko Ezoe ◽  
Tatsutoshi Nakahata ◽  
...  

Abstract Several reports have implicated canonical Wnt/β-catenin pathway in murine and human hematopoietic stem/progenitor cells (HSC/HPCs) ex vivo expansion. In addition, it was demonstrated augmentation of hematopoietic repopulating ability in vivo by post transplantation treatment with an ATP-competitive GSK-3 inhibitor, which leads to activation of intrinsic β-catenin. Conversely, it is also reported that constitutive activation of β-catenin enforced cell cycle entry of murine HSCs, thereby, exhausting the long-term repopulating cell pool and leading to hematopoietic failure associated with loss of multilineage differentiation. In this way, the precise roles of individual molecules concerning in canonical Wnt/β-catenin pathway for normal hematopoiesis have not been elucidated. In this study, we examined the effects of GSK-3 inhibition on stem-cell maintenance, progenitor cell expansion, and lineage decisions of murine and human HSC/HPCs. At first, the expression and localization of β-catenin in human CD34+ HSC/HPCs treated with GSK-3 inhibitor 9 (6-bromoindirubin-3-oxime) (GI9) was observed with confocal microscopy. After the treatment for 24 hrs, expression of β-catenin in vehicle-treated (negative control; NC) cells was scarcely detected except for the membrane-bounded form. On the other hand, in GI9-treated cells, β-catenin accumulated in their nucleus in a dose dependent manner. These results suggested that GI9-treatment activates intrinsic β-catenin in human HSC/HPCs. Next, CD34+ HSC/HPCs were cultured for 7 days in a serum-free medium containing with cytokines (SCF, FL, TPO, IL-6 and sIL-6R) and also with 2μM, 10μM of GI9 or vehicle. After 7 days culture, total viable cells and CD34+ cells were expanded 31.6±4.6 and 17.9±3.8 fold in NC cells, respectively (n=3). However, GI9-treatment could not maintain a proportion of CD34+ cells compared with NC significantly caused the growth inhibition in a dose dependent manner. From the analysis of cumulative distribution of first cell division among the cells treated with GI9 or vehicle, GI9-treatment caused delayed cell cycling especially in fractionated immature CD34+CD38− cells. In addition, GSK-3 inhibition lost SCID repopulating cells (SRCs) as tested in the NOD/SCID mouse model (SRCs was calculated to be 1 in 8,452 NC cells vs. in 45,503 GI9-treated cells using limiting dilution methods). These results suggested that activation of intrinsic β-catenin followed GSK-3 inhibition suppressed self-renewal of immature hematopoietic cells via modulating its cell cycle kinetics. Next, as for the multipotency of HSC/HPCs after the culture, the distribution pattern of immunophenotype and the colony forming ability were evaluated. About 80% of expanded cells expressed myeloid marker, CD33 in our culture system, however, GI9-treatment perturbed myeloid differentiation of CD34+ HSC/HPCs but induced the differentiation toward to megakaryocyte and erythroid lineages. Furthermore, in methylcellulose assay, although expanded cells with GI9-treatment generated all types of progenitors, GI9-treatment was inferior significantly in terms of expansion rate of myeloid progenitor, CFU-GM and superior in formation of erythroid progenitor, BFU/CFU-E compared with NC (No. of CFU-GM/1000 cells 151±65.8 vs. 284±17.0, No. of BFU/CFU-E/1000 cells 132±18.5 vs. 32.7.±7.0, respectively) (p<0.05, n=3). Similarly, in murine model, GI9-treatment tended to convert differentiation potential of common myeloid progenitor (CMP) from granulocyte and macrophage progenitor (GMP) to megakaryocyte and erythroid progenitor (MEP). As for this mechanism, we found that activated β-catenin suppresses the transcriptional activity of C/EBPα, which is essential transcription factor for granulocyte development, while it promotes the function of GATA1, essential transcription factor for megakaryocyte and erythrocyte development during the differentiation of HSC/HPCs. In addition, β-catenin competitively impeded the interaction between C/EBPα and its transcriptional coactivator, CBP/p300 in coimmunoprecipitaion analysis. Together, these results indicated that intrinsic β-catenin was supposed to play an important role in self-renewal and multipotency of HSC/HPCs and control the balance of lineage commitment of HSC/HPCs for normal hematopoiesis, presumably by regulating the interaction with essential transcription factors.


2018 ◽  
Vol 18 (5) ◽  
pp. 739-746 ◽  
Author(s):  
Raj Kaushal ◽  
Nitesh Kumar ◽  
Archana Thakur ◽  
Kiran Nehra ◽  
Pamita Awasthi ◽  
...  

Abstract: Background: After the discovery of cisplatin, first non platinum anticancer drugs having excellent efficacy were budotitane and TiCl2(cp)2 but action mechanism is not clear. Therefore, we hereby reporting synthesis and biological activities novel titanium complexes to explore their mode of action. Objectives: Synthesis, spectral characterization, antibacterial and anticancer activity of some titanium complexes. Antibacterial studies on various bacterial strains and anticancer studies on HeLa, C6, CHO cancerous cell lines have been performed. Further, the cell death mechanistic study was done on CHO cell lines. Method: Titanium complexes with and without labile groups have been synthesized by reacting of TiCl4 with nitrogen containing ligands viz. 1,2-diaminocyclohexane, 1,10-Phenanthroline, adamantylamine, 2,2'-bipyridine, 4,4'-dimethyl-2,2'-bipyridine in predetermined molar ratios. Antibacterial and anticancer studies were performed by agar well diffusion method and MTT assay respectively. Cell cycle analysis is done by using flow cytometry. Results: Complex 2 i.e TiCl2(Phen)2 showed better activity than other complexes as an antibacterial as well as anticancer agent. Phase contrast imaging indicates that observed morphological changes of cells was dose dependent. Cell death mechanistic study have shown the increase in sub G0 phase population as well as formation of blebbing and fragmentation of chromatin material which is an indicative measure of apoptosis. Conclusion: Complex 2 proved to be more effective bactericide and cytotoxic agent. Cell cycle analysis showed cell arrest in G0 phase. Apoptosis percentage was found to increase in a dose dependent manner. So, prepared titanium complexes can be put to use as an important chemotherapeutic agents.


2019 ◽  
Vol 19 (4) ◽  
pp. 557-566 ◽  
Author(s):  
Nerella S. Goud ◽  
Mahammad S. Ghouse ◽  
Jatoth Vishnu ◽  
Jakkula Pranay ◽  
Ravi Alvala ◽  
...  

Background: Human Galectin-1, a protein of lectin family showing affinity towards β-galactosides has emerged as a critical regulator of tumor progression and metastasis, by modulating diverse biological events including homotypic cell aggregation, migration, apoptosis, angiogenesis and immune escape. Therefore, galectin-1 inhibitors might represent novel therapeutic agents for cancer. Methods: A new series of heterocyclic imines linked coumarin-thiazole hybrids (6a-6r) was synthesized and evaluated for its cytotoxic potential against a panel of six human cancer cell lines namely, lung (A549), prostate (DU-145), breast (MCF-7 & MDA-MB-231), colon (HCT-15 & HT-29) using MTT assay. Characteristic apoptotic assays like DAPI staining, cell cycle, annexin V and Mitochondrial membrane potential studies were performed for the most active compound. Furthermore, Gal-1 inhibition was confirmed by ELISA and fluorescence spectroscopy. Results: Among all, compound 6g 3-(2-(2-(pyridin-2-ylmethylene) hydrazineyl) thiazol-4-yl)-2H-chromen-2- one exhibited promising growth inhibition against HCT-15 colorectal cancer cells with an IC50 value of 1.28 ± 0.14 µM. The characteristic apoptotic morphological features like chromatin condensation, membrane blebbing and apoptotic body formation were clearly observed with compound 6g on HCT-15 cells using DAPI staining studies. Further, annexin V-FITC/PI assay confirmed effective early apoptosis induction by treatment with compound 6g. Loss of mitochondrial membrane potential and enhanced ROS generation were confirmed with JC-1 and DCFDA staining method, respectively by treatment with compound 6g, suggesting a possible mechanism for inducing apoptosis. Moreover, flow cytometric analysis revealed that compound 6g blocked G0/G1 phase of the cell cycle in a dose-dependent manner. Compound 6g effectively reduced the levels of Gal-1 protein in a dose-dependent manner. The binding constant (Ka) of 6g with Gal-1 was calculated from the intercept value which was observed as 1.9 x 107 M-1 by Fluorescence spectroscopy. Molecular docking studies showed strong interactions of compound 6g with Gal-1 protein. Conclusion: Our studies demonstrate the anticancer potential and Gal-1 inhibition of heterocyclic imines linked coumarin-thiazole hybrids.


Sign in / Sign up

Export Citation Format

Share Document